However, HER2 positive GC patients frequently develop resistance to trastuzumab [45, 46] through a mechanism that remains poorly understood, although intratumoral heterogeneity may represent one cause of cancer treatment resistance [47, 48]. This evidence concerns the gene ERBB2 and cancer.